## **An Enantioselective Synthesis of 2-lsocephem and 2-lso-oxacephem Nuclei**

## **Hajime Nitta, Minoru Hatanaka,\* and Toshiyasu lshimaru**

*The Institute of Scientific and Industrial Research, Osaka University, Mihogaoka, Ibaraki, Osaka 567, Japan* 

A stereocontrolled synthesis of optically active 2-isocephem and 2-iso-oxacephem nuclei **is** described starting from L-aspartic acid.

2-Isocephems and 2-iso-oxacephems have been reported to have potent antibacterial activity.<sup>1,2</sup> However, most previous syntheses have led to racemic compounds and could not give optically active derivatives without resolution.<sup>2c,3</sup> Herein we report a stereocontrolled synthesis of optically active 2-isocephalosporin **(1)** and its oxa analogue **(2)** starting from L-aspartic acid. The key step is the stereoselective introduction of the azide group into L-aspartic acid leading to the amino acid *(6),* which can be converted via a four-component condensation into chiral cis-3-azidoazetidinones.



The anhydride  $(3)$  was reduced with NaBH<sub>4</sub> in tetrahydrofuran (THF) at  $-20$  to  $0^{\circ}$ C to afford the lactone **(4)**  $\overline{92\%}$ yield, m.p. 106-108 °C,  $[\alpha]_D^{25}$  -61° (c 1.0, EtOH)}. The dianion of **(4),** [lithium di-isopropylamide **(LDA;** 2 equiv.),  $-67$  °C] was treated with toluene-p-sulphonyl azide followed by an excess of chlorotrimethylsilane to give exclusively the expected *trans*-azide (5)<sup>4†</sup> in 58% yield. Attempted opening

*i.* The spectral properties of all new compounds were in accord with the proposed structure. Selected physical data: (5): m.p. 110-111 °C;  $[\alpha]_D^{25}$  –69° (c 1.0, EtOH); i.r. (KBr) 2100, 1780, and 1680 cm<sup>-1</sup>. (11): m.p. 149-150 °C; [α]<sub>D</sub><sup>25</sup> - 34.2° (c 1.0, EtOH); λ<sub>max</sub> (EtOH) 269 nm (log *E* 4.22); lH n.m.r. (CDCI,) 6 3.79 (lH, m), 3.94 (lH, dd, J9.5, 11.3 Hz), 4.60 (lH, dd, *J* 3.7, 11.3 Hz), 5.27 (lH, d, *J* 5.2 Hz), 5.28 (lH, d, *J* 13.5 Hz), 5.43 (lH, d, *J* 13.5 Hz), 7.40 (lH, **s),** 7.60 (2H,J 8.9 Hz), and 8.23 (2H, d, *J* 8.9 Hz). (12): m.p. 147--148 °C;  $[\alpha]_D$ <sup>25</sup>  $-46.6^{\circ}$  (c 0.5, dioxane); i.r. (KBr) 2100, 1760, and 1700 cm<sup>-1</sup>;  $\lambda_{\text{max}}$  $(EtOH)$  302 nm (log  $\epsilon$  4.12); <sup>1</sup>H n.m.r. (CDCl<sub>3</sub>)  $\delta$  3.03-3.16 (2H, m), 3.94 (lH, m) ,5.22 **(1** H, d, *J* 5.1 Hz) ,5.29 (lH, **d** , *J* 13.3 Hz) **,5.4 1** (lH, d, J 13.3 Hz), 7.13 (lH, **s),** 7.60 (2H, d, *J* 8.8 Hz), and 8.24 (2H, d, *J* 8.8 Hz).



**Scheme 1.** PNB = p-nitrobenzyl, Boc = t-butoxycarbonyl. *Reagents:* i, NaBH<sub>4</sub> (1 equiv.), THF,  $-20$  to  $0^{\circ}$ C, 2 h, followed by benzene, reflux, 3 h; ii, LDA (2.1 equiv.), THF,  $-78$  to  $-20^{\circ}$ C, 1 h, then  $p$ -MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>N<sub>3</sub> (1.2 equiv.), THF, -78 °C, 1 h, followed by Me<sub>3</sub>SiCl,  $-78$  to  $0^{\circ}$ C; iii,  $CF_3CO_2H$ , then Amberlite IRA-45, MeOH-H20, 0°C; iv, (a) for preparation of **(7):** 30% aqueous HCHO,  $p$ -O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NC, MeOH, room temp., 10 h; (b) for preparation of (8): (EtO)<sub>2</sub>CHCHO, p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NC, MeOH, room temp., 10 h; v, MeSO<sub>2</sub>Cl, Et<sub>3</sub>N, THF, room temp., 10 h, then  $N_2O_4$ , CHCl<sub>3</sub>, AcONa,  $0^{\circ}$ C, 1 h, followed by CCl<sub>4</sub>, reflux, 3 h; vi, CF<sub>3</sub>CO<sub>2</sub>H; vii, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 3 h; viii, MeSO<sub>2</sub>Cl, Et<sub>3</sub>N, THF, then H<sub>2</sub>S, CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 0°C.

of the lactone ring of *(5)* with aqueous alkali led to elimination of t-butoxyformamide. However, after removal of the t-butoxycarbonyl group with trifluoroacetic acid, neutralization of the resulting trifluoroacetate with Amberlite IRA-45 in aqueous methanol also effected opening of the lactone ring to give the crystalline amino acid  $(6)$   $\{m.p. 135 \rightarrow 137 \degree C$  $\overline{(\text{decomp.})}, \overline{[\alpha]_{D}^{25} - 149^{\circ} (c \ 1.0, H_{2}O)}$  in 76% yield.

The amino acid *(6)* was subjected to four-component condensation for constructing the azetidinone ring using  $p$ -nitrobenzyl isocyanide<sup>5</sup> as the isonitrile. An equimolar mixture of the amino acid **(6),** formaldehyde, and p-nitrobenzyl isocyanide was stirred in methanol at room temperature for 10 h to give the cis-azetidinone **(7)** in 95% yield. When **2,2-diethoxyacetaldehyde** was used instead of formaldehyde, the cis-azetidinone **(8)** was obtained in 93% yield as a *ca.* 1 : 1 diastereoisomeric mixture. The resulting monocyclic azetidinones can serve as versatile intermediates for synthesis of a variety of bicyclic 6-lactam compounds. For example, compound **(8)** could be readily transformed into 2-isocephalosporin and 2-iso-oxacephalosporin.

Methanesulphonylation of the hydroxy group of **(8)** followed by conversion of the p-nitrobenzylamide group into the p-nitrobenzyl ester *via* N-nitrosation gave compound **(9)** in 57% yield, which corresponded to the key intermediate in the synthesis of 2-iso-oxacephalosporins and 2-isocephalosporins reported by Doyle *et a1.2a,b* Thus, according to the Doyle's procedure, compound **(9)** was converted into the 7-azido-2 iso-oxacephem **(11)** *via* **(10)** by treatment with trifluoroacetic acid followed by triethylamine. On the other hand, methanesulphonylation of **(10)** followed by treatment with hydrogen sulphide gave the 7-azido-2-isocephem **(12).** Compounds **(12)**  and **(11)** can be converted into the 2-isocephalosporin and 2-iso-oxacephalosporin derivatives **(1)** and **(2)** having a variety of substituents R by standard sequences consisting of reduction of the azide group, acylation, and removal of the protective groups.

*Received, 8th September 1986; Com. I282* 

## **References**

- 1 For a review see: F. A. Jung, **W.** R. Pilgrim, J. P. Poyser, and P. J. Siret, in 'Topics in Antibiotic Chemistry,' Vol. 4, ed. P. G. Sammes, Ellis Horwood, Chichester, 1980, p. 93.
- 2 (a) T. **W.** Doyle, B. Belleau, B-Y. Luh, T. T. Conway, M. Menard, J. L. Douglas, D. T-W. Chu, G. Lim, L. R. Morris, P. Rivest, and M. Casey, *Can. J. Chem.,* 1977, *55,* 484; (b) T. **W.** Doyle, J. L. Douglas, B. Belleau, J. Meunier, and B-Y. Luh, *ibid.,* 1977, *55,*  2873; *(c)* T. T. Conway, G. Lim, J. L. Douglas, M. Menard, T. **W.**  Doyle, P. Rivest, D. Homing, L. R. Morris, and D. Cimon, *ibid.,*  1978, *56,* 1335; (d) D. B. Bryan, R. F. Hall, K. G. Holden, **W. F.**  Huffman, and J. G. Gleason, *J. Am. Chem.* **SOC.,** 1977, **99,** 2354.
- 3 An approach to optically active 2-iso-oxacephalosporin has been reported: A. K. Bose, J. E. Vincent, **I.** F. Fernandez, K. Gala, and M. **S.** Manhas in 'Recent Advances in the Chemistry of 6-Lactam Antibiotics' (Proceedings of the 2nd International Symposium), ed. G. **I.** Gregory, The Royal Society of Chemistry, Special Publications No. 38, 1980, p. 80.
- 4 Alkylation of lactones of type **(4)** gave mainly trans-alkylated products together with significant amounts of the cis-isomers: G. **J.**  McGarvey, R. N. Hiner, **Y.** Matsubara, and T. Oh, *Tetrahedron Lett.,* 1983, **24,** 2733.
- *5* M. Hatanaka, H. Nitta, and T. Ishimaru, *Tetrahedron Lett.,* 1984, *25,* 2387.